A Transformation-Defective Polyomavirus Middle T Antigen with a Novel Defect in PI3 Kinase Signaling.

作者: Deborah Denis , Cecile Rouleau , Brian S. Schaffhausen

DOI: 10.1128/JVI.01774-16

关键词:

摘要: Middle T antigen (MT), the principal oncoprotein of murine polyomavirus, transforms by association with cellular proteins. Protein phosphatase 2A (PP2A), YAP, Src family tyrosine kinases, Shc, phosphatidylinositol 3-kinase (PI3K), and phospholipase C-γ1 (PLCγ1) have all been implicated in MT transformation. Mutant dl1015, deletion residues 338 to 347 C-terminal region, has an enigma, because basis for its transformation defect not apparent. This work probes dl1015 region MT. Because is proline rich, hypothesis that it targets homology domain 3 (SH3) domains was tested, but mutation putative SH3 binding motif did affect During this work, two point mutants, W348R E349K, were identified as defective. Extensive analysis E349K mutant described here. Similar wild-type MT, associates PP2A, PI3 kinase, PLCγ1. The examined determine mechanism defect. Assays cell localization membrane targeting showed no obvious difference localization. normal assayed vitro kinase phosphopeptide mapping. Shc activation confirmed phosphorylation. Association type 1 PI3K demonstrated coimmunoprecipitation, showing both subunits activity. Nonetheless, expression mutants failed lead known downstream PI3K, Akt Rac-1. Strikingly, despite cells expressing elevate (3,4,5)-trisphosphate (PIP3) mutant-expressing cells. These results indicate a novel unsuspected aspect control. IMPORTANCE gene coding middle (MT) polyomavirus oncogene most responsible tumor formation. Its study history uncovering aspects mammalian regulation. importance activity phosphorylation are examples insights coming from describes new unable transform like wild regulation signaling. Previous defective they bind enzyme bring membrane. recruit type, fail level PIP3, product used signal PI3K. As result, activate either or Rac1, explaining

参考文章(85)
AE Salcini, PG Pelicci, Tony Pawson, I Nicoletti, J McGlade, G Pelicci, Formation of Shc-Grb2 complexes is necessary to induce neoplastic transformation by overexpression of Shc proteins. Oncogene. ,vol. 9, pp. 2827- 2836 ,(1994)
T. Hunter, M.A. Hutchinson, W. Eckhart, Polyoma middle-sized T antigen can be phosphorylated on tyrosine at multiple sites in vitro. The EMBO Journal. ,vol. 3, pp. 73- 79 ,(1984) , 10.1002/J.1460-2075.1984.TB01763.X
S. H. Cheng, R. Harvey, P. C. Espino, K. Semba, T. Yamamoto, K. Toyoshima, A. E. Smith, Peptide antibodies to the human c-fyn gene product demonstrate pp59c-fyn is capable of complex formation with the middle-T antigen of polyomavirus. The EMBO Journal. ,vol. 7, pp. 3845- 3855 ,(1988) , 10.1002/J.1460-2075.1988.TB03270.X
C. J. Dawe, T. L. Benjamin, K. Ballmer-Hofer, D. A. Talmage, R. Freund, G. Mandel, Variations in polyoma virus genotype in relation to tumor induction in mice. Characterization of wild type strains with widely differing tumor profiles. American Journal of Pathology. ,vol. 127, pp. 243- 261 ,(1987)
G Magnusson, M G Nilsson, S M Dilworth, N Smolar, Characterization of polyoma mutants with altered middle and large T-antigens. Journal of Virology. ,vol. 39, pp. 673- 683 ,(1981) , 10.1128/JVI.39.3.673-683.1981
G Magnusson, P Berg, Construction and analysis of viable deletion mutants of polyoma virus. Journal of Virology. ,vol. 32, pp. 523- 529 ,(1979) , 10.1128/JVI.32.2.523-529.1979
B Schaffhausen, T L Benjamin, Comparison of phosphorylation of two polyoma virus middle T antigens in vivo and in vitro. Journal of Virology. ,vol. 40, pp. 184- 196 ,(1981) , 10.1128/JVI.40.1.184-196.1981
Yardena Samuels, Victor E. Velculescu, Oncogenic Mutations of PIK3CA in Human Cancers Cell Cycle. ,vol. 3, pp. 1221- 1224 ,(2004) , 10.4161/CC.3.10.1164
Egon Ogris, Ingrid Mudrak, Elsa Mak, Daryl Gibson, David C. Pallas, Catalytically Inactive Protein Phosphatase 2A Can Bind to Polyomavirus Middle Tumor Antigen and Support Complex Formation with pp60c-src Journal of Virology. ,vol. 73, pp. 7390- 7398 ,(1999) , 10.1128/JVI.73.9.7390-7398.1999